Percentile-Based Fetal Growth Velocity as a Predictor of Adverse Neonatal Outcomes in Fetal Growth Restriction and Small-for-Gestational-Age Pregnancies
Brunton, J.; Salameh, M. A.; Branda, M.; Stetson, R. C.; Schenone, M.; Cooper, K.; Larish, A.; Theiler, R. N.
Show abstract
Background: Pregnancies complicated by fetal growth restriction are at increased risk of fetal demise and adverse neonatal outcomes. Distinguishing growth-restricted fetuses from constitutionally small ones remains challenging. Given the variability in current diagnostic criteria and the importance of identifying at-risk fetuses, fetal growth velocity has emerged as a predictor of adverse neonatal outcomes. Objective: To evaluate whether percentile-based fetal growth velocity, defined as change in estimated fetal weight percentile per week, predicts adverse neonatal outcomes in pregnancies affected by fetal growth restriction or small-for-gestational-age neonates. The primary aim was to determine the relationship between growth velocity and a composite of adverse neonatal outcomes. Study Design: This was a retrospective cohort study of pregnant patients 18 - 45 years old who delivered between August 2017 to December 2022 in a single healthcare system. Patients were excluded who had fewer than 2 ultrasounds after 16 weeks gestation, genetic or anatomic abnormalities, or a multiple gestation. Results: 300 patients met all inclusion criteria, and most patients (n=199) delivered at the tertiary care center. Three had an intrauterine fetal demise at a mean gestational age of 35w3d. 74 neonates were admitted to the NICU with a mean length of stay of 8.5 days; 29 required respiratory support. No neonatal deaths occurred. In fetuses with initial estimated fetal weight <3rd percentile (n=33), the probability of composite outcome was increased (50%, 95% CI 44.8-55.2) compared to those >50th percentile (5%, 95% CI 3.7-6.6). In the 3-10th and 10 - 50th percentile subgroups with decelerated growth, composite outcome rates were also increased (56.2% and 44.1%) compared to those with neutral or increased growth velocity. Conclusion: Percentile-based fetal growth velocity is a simple calculation that correlates with adverse neonatal outcomes regardless of initial estimated fetal weight. As fetal growth velocity decreased, our cohort saw increased rates of adverse outcomes. Change in EFW percentile normalizes for gestational age and allows ease of clinical interpretation. Decelerated growth identified fetuses at highest risk, suggesting growth velocity as a useful metric in routine surveillance.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Changes in pregnancy-related serum biomarkers early in gestation are associated with later development of preeclampsia 94%
- Ranked severe maternal morbidity index for population-level surveillance at delivery hospitalization based on hospital discharge data 93%
- Experience in the implementation of the early warning sign system in obstetric patients (Maternal Early Warning Criteria, MEWC) during early postpartum. A prospective observational study 93%
Similar papers in this journal
- Abnormalities of the rib growth plate and the periphysis of previously healthy infants and toddlers dying suddenly and unexpectedly 88%
- Macrophage polarization in cesarean scar diverticulum 87%
- Mid-Regional pro-Adrenomedullin (MR-proADM), C-Reactive Protein (CRP) and Other Biomarkers in the Early Identification of Disease Progression in COVID-19 Patients in the Acute NHS Setting 86%
Similar papers in this journal
- Comparison of first trimester dating methods for gestational age estimation and their implication on preterm birth classification in a North Indian cohort 94%
- Maternal and perinatal characteristics and outcomes of pregnancies complicated with COVID-19 in Kuwait 93%
- Reduction in Spontaneous and Iatrogenic Preterm Births in Twin Pregnancies During COVID-19 Lockdown in Melbourne, Australia: A Multicenter Cohort Study 93%
Similar papers in this journal
- Integrating clinical factors and parity-specific models with molecular biomarkers to better predict the risk of preterm birth in asymptomatic women 95%
- Neonatal outcomes after proteomic biomarker-guided intervention: the AVERT PRETERM TRIAL 93%
- Soluble angiotensin-converting enzyme 2 as a prognostic biomarker for disease progression in patients infected with SARS-CoV-2 86%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.